Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2013 / Cilt: 22 - Sayı: 1

Fokal segmental glomerüloskleroz ve membranöz glomerülopatili hastalarda antiproteinürik tedavinin lipit düzeylerine etkisi

The effect of antiproteinuric treatment on lipid levels in patients with focal segmental glomerulosclerosis and membranous glomerulopathy

Pages
72–77
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Key words: Hyperlipidemia, Primary glomerular disease, Proteinuria, Steroid, Statin

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The primary objective of our study was to investigate effects of antiproteinuric treatment on lipid levels of patients with idiopathic focal segmental glomerulosclerosis (FSGS) or membranous glomerulonephritis (MGN).
📊
Key Findings & Data:MATERIAL and METHODS: The clinical and laboratory data of the patients were recorded at three-month intervals during 18 months of follow-up.
💡
Conclusion & Impact:Key words: Hyperlipidemia, Primary glomerular disease, Proteinuria, Steroid, Statin
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The primary objective of our study was to investigate effects of antiproteinuric treatment on lipid levels of patients with idiopathic focal segmental glomerulosclerosis (FSGS) or membranous glomerulonephritis (MGN). MATERIAL and METHODS: The clinical and laboratory data of the patients were recorded at three-month intervals during 18 months of follow-up. Patients with non-nephrotic proteinuria without hypoalbuminemia received conservative treatment while those with more severe disease received steroid therapy as well. Lipid parameters in the two groups and the factors effective on these parameters were investigated. RESULTS: Sixty eight patients (36 with FSGS, 32 with MG) were included. The mean age of the patients and the follow-up period were 39.6±16.6 years and 16.4±8.9months, respectively. 36 (53%) patients received steroid therapy. The percentage of patients taking antilipemic treatment was statistically significantly higher in the group taking steroid therapy. LDL cholesterol levels were higher at the beginning in patients taking steroid therapy but the difference disappeared after the ninth month. Total and LDL cholesterol levels showed a negative correlation with albumin levels and a positive correlation with proteinuria level. CONCLUSION: Treatment of hyperlipidemia in nephrotic syndrome should be directed towards increasing serum albumin levels, and therefore treatment of the glomerular disease. Antilipidemic therapies should be considered in patients who do not respond to other antiproteinuric treatment. Key words: Hyperlipidemia, Primary glomerular disease, Proteinuria, Steroid, Statin

Özet

AMAÇ: Çalışmamızın amacı, idiopatik fokal segmental glomerüloskleroz (FSGS) ve membranöz glomerülopati (MGN) tanılı hastalarda antiproteinürik tedavinin lipit düzeylerine etkisini incelemektir. GEREÇ ve YÖNTEMLER: Hastaların 18 aylık takibi boyunca üç ay aralarla klinik ve laboratuar bulguları kaydedildi. Hipoalbüminemisi olmayan ve non-nefrotik düzeyde proteinürisi olan hastalar konservatif tedavi alırken; daha ağır proteinürisi olan hastalar aynı zamanda steroid tedavisi aldı. Her iki grupta da lipit parametreleri ve bu parametreler üzerine etkili faktörler araştırıldı. BULGULAR: 68 hasta (36 FSGS, 32 MGN) çalışmaya alındı. Ortalama yaşları ve takip süreleri sırası ile 39,6±16,6 yıl ve 16,4±8,9 ay olarak saptandı. 36 (%53) hasta steroid tedavisi aldı. Anti-lipemik ilaç kullanan hasta oranı steroid tedavisi gören hasta grubunda daha yüksekti. Başlangıç LDL kolesterol düzeyleri steroid tedavisi alan grupta daha yüksek olsa da bu fark dokuzuncu aydan sonra kayboldu. Total ve LDL kolesterol düzeyleri albümin ile negatif, proteinüri düzeyi ile pozitif korele bulundu. SONUÇ: Nefrotik sendromda hiperlipideminin tedavisi serum albümin düzeyini yükseltmeye, dolayısıyla glomerüler hastalığın tedavisine yönelik olmalıdır. Anti-lipemik ajanlar diğer antiproteinürik tedaviye yanıt alınamayan hastalarda uygulanmalıdır.

🔖

Cite This Article

TÜRKMEN, A., ŞAR, F., KÜÇÜK, H., KÜÇÜK, M., ÖZKAN, O., KAZANCIOĞLU, R., AYDIN, Z., GÜRSU, M., ÖZTÜRK, S., YAZICI, H. (2022). Fokal segmental glomerüloskleroz ve membranöz glomerülopatili hastalarda antiproteinürik tedavinin lipit düzeylerine etkisi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 22 - Sayı: 1, 72–77. https://ajindex.com/articles/636324

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Baxter JH, Goodman HC, Allen JC: Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest 1961; 40: 490 Stenvinkel P, Berglund L, Heimburger O, Petersson E, Alvestrand A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993; 44: 1116-1123
  2. Radhakrishnan J, Appel AS, Valeri A, Appel GB: The nephrotic yndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993; 22: 135-142
  3. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased isk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993: 4: 638-642
  4. Moorhead JF, Chan MK, El-Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and ubulointerstitial disease. Lancet 1982; 2: 1309-1311
  5. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Kidney Int 1995; 47: 907 Keane WF, Kasiske BL, O’Donnell MP: Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-271
  6. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm Jr RLevin A, Masri B, Parekh R, Wanner C, Wheeler DC, Wilson PWF: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Working Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initative. Am J Transplant 2004; 4 Suppl 7: 13 Wanner C, Krane V, Metzger T, Quaschning T: Lipid changes and statins in chronic renal insufficiency and dialysis. J Nephrol 2001; 14 (Suppl 4): 76-80
  7. Wheeler DC, Bernard DB: Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 1994; 23: 331-346
  8. Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188-198
  9. Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler CW, Varghese Z, Williams JD, Walls J, Moorhead JF: Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993; 44: 1124-1129
  10. Demant T, Mathes C, Gutlich K, Bedynek A, Steinhauer HBBosch B, Packard CJ, Warwick GL: A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patientsKidney Int 1998; 54: 2064
  11. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones M, Shepherd J: Metabolism of apolipoprotein B-containing ipoptoteins in subjects with nephritic-range prote